• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.67% Nasdaq Up1.47%

    More On UCBJF

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials

    • Income Statement
    • Balance Sheet
    • Cash Flow

    UCB S.A. (UCBJF)

    -Other OTC
    69.54 Up 0.94(1.37%) 1:38PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    UCB S.A.
    Allée de la Recherche, 60
    Brussels, 1070
    Belgium - Map
    Phone: 32 2 559 99 99
    Fax: 32 2 559 99 00
    Website: http://www.ucb.com

    Details 
    Index Membership:N/A
    Sector:N/A
    Industry:N/A
    Full Time Employees:8,535

    Business Summary 

    UCB S.A., a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The company’s product pipeline includes brivaracetam as an adjunctive therapy for epilepsy POS; Vimpat for various types of epilepsy; UCB4942 for drug resistant epilepsy; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 for immune-inflammatory diseases; UCB7665 for immunological diseases; and dapirolizumab pegol for systemic lupus erythematosus. The company has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on UCB S.A.

    Key Executives 
     PayExercised
    Mr. Jean-Christophe Tellier ,
    Chief Exec. Officer and Exec. Director
    N/AN/A
    Mr. Detlef Thielgen , 54
    Chief Financial Officer
    N/AN/A
    Mr. Mark D. McDade , 60
    Chief Operating Officer
    N/AN/A
    Dr. Ismail Kola Ph.D., 58
    Chief Scientific Officer and Head of New Medicines Patient Value Unit
    N/AN/A
    Ms. Anna S. Richo , 54
    Gen. Counsel
    N/AN/A
    Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.